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Abstract
Background and Aims: The hepatitis C virus (HCV) invariably shows wide heterogeneity in infected patients, referred to as a
quasispecies population. Massive amounts of genetic information due to the abundance of HCV variants could be an
obstacle to evaluate the viral genetic heterogeneity in detail.
Methods: Using a newly developed massive-parallel ultra-deep sequencing technique, we investigated the viral genetic
heterogeneity in 27 chronic hepatitis C patients receiving peg-interferon (IFN) a2b plus ribavirin therapy.
Results: Ultra-deep sequencing determined a total of more than 10 million nucleotides of the HCV genome, corresponding
to a mean of more than 1000 clones in each specimen, and unveiled extremely high genetic heterogeneity in the genotype
1b HCV population. There was no significant difference in the level of viral complexity between immediate virologic
responders and non-responders at baseline (p=0.39). Immediate virologic responders (n=8) showed a significant reduction
in the genetic complexity spanning all the viral genetic regions at the early phase of IFN administration (p=0.037). In
contrast, non-virologic responders (n=8) showed no significant changes in the level of viral quasispecies (p=0.12),
indicating that very few viral clones are sensitive to IFN treatment. We also demonstrated that clones resistant to direct-
acting antivirals for HCV, such as viral protease and polymerase inhibitors, preexist with various abundances in all 27
treatment-naı ¨ve patients, suggesting the risk of the development of drug resistance against these agents.
Conclusion: Use of the ultra-deep sequencing technology revealed massive genetic heterogeneity of HCV, which has
important implications regarding the treatment response and outcome of antiviral therapy.
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Introduction
Hepatitis C virus (HCV) is classified as a member of the
Flaviviridae family [1] and has an approximately 9.6-kb single-
stranded RNA genome. This RNA genome encodes a large
precursor polyprotein, which is cleaved by viral and host proteases
to generate at least 10 functional viral proteins; core, envelope (E)-
1, E2, p7, nonstructural protein (NS)-2, NS3, NS4A, NS4B,
NS5A, and NS5B [2,3]. A strong characteristic of HCV infection
is its significant genetic diversity, the consequence of the absence of
proofreading activity in RNA-dependent RNA polymerase [4],
and the high level of viral replication during its life cycle [5]. The
mean frequency of nucleotide alterations occurring in HCV RNA
is calculated to be between 1.4610
3 and 1.9610
3 substitutions per
nucleotide per year [6,7]. As a result, the infecting HCV clones in
each patient invariably show population diversity with a high
degree of genetic heterogeneity. The collection of viruses in a
population of closely related but non-identical genomes is referred
to as a quasispecies [8,9], and the dominant viral population may
be evolving as a result of its viral replicative fitness and concurrent
immune selection pressures that drive clonal selection.
It is reasonable to assume that the viral pathogenesis and
sensitivity to treatment are affected by the generation of escape
mutants through immune evasion and the modification of
virulence characteristics by anti-viral treatment [10]. Thus, certain
viral mutations have important implications for the pathogenesis
of the viral disease and the sensitivity to antiviral therapy. Several
studies have attempted to associate genetic heterogeneity or
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24907number of mutations with pathogenesis and treatment outcome.
However, the abundant diversity and complexity of the chroni-
cally-infected HCV has been an obstacle to evaluate the viral
genetic heterogeneity in detail. In this respect, the recent
introduction of ultra-deep sequencing technology, capable of
producing millions of DNA sequence reads in a single run, is
rapidly changing the landscape of genome research [11,12]. One
application of ultra-deep sequencing was the identification of rare
minority drug resistant clones of human immunodeficiency virus,
which are not detectable by standard sequencing techniques [13–
15]. Moreover, the recent study using 454/Roche pyrosequencing
technology clarified the transmission bottlenecks by measuring the
population structure within patients with HCV infection [16].
In this study, we used for the first time ultra-deep sequencing
with Illumina Genome Analyzer II (Illumina, San Diego, CA) and
determined the pictures of viral quasispecies of genotype 1b HCV
in patients receiving peg-interferon (IFN) a2b plus ribavirin (RBV)
to clarify the significance of the viral genetic complexity in the
pathophysiology of HCV infection and the treatment outcome of
the current IFN-based therapy for HCV-infected patients. Because
our main objective was to determine whether the HCV sequence
variation itself is responsible for the sensitivity or resistance to
antiviral therapy, we compared the composition of the HCV
population complexity 1 week after IFN administration in patients
who showed a prompt decrease in HCV viremia with those in
whom there was no reduction in the serum HCV RNA levels after
the initiation of IFN treatment. We also examined the prevalence
of drug-resistant mutations to direct-acting antivirals (DAAs) for
HCV in treatment-naı ¨ve HCV-infected patients, based on the fact
that drug-resistant mutations already exist in treatment-naı ¨ve
patients with various pathogenic virus infections, such as human
immunodeficiency viruses [14,17].
Results
Validation of multiplex ultra-deep sequencing of the HCV
genome
We performed a massive parallel ultra-deep sequencing run on
the Illumina Genome Analyzer II platform using multiplex tagging
methods. First, we conducted a control experiment to validate the
efficacy and error rates in ultra-deep sequencing of the viral
genome. For this purpose, we used a plasmid encoding full-length
HCV [18] as a template and determined the plasmid-derived
whole HCV sequence. The ultra-deep sequencing platform
provided us the full-length HCV genome information derived
from the plasmids with a mean coverage of 1674.3 at each
nucleotide site (Table 1). Errors comprised insertions (1.0%),
deletions (4.2%), and nucleotide mismatches (94.8%) and the
overall error rates by multiplex ultra-deep sequencing were
determined to be a mean of 0.0010 per bp. Next we confirmed
that the high-fidelity PCR amplification with HCV-specific primer
sets followed by multiplex ultra-deep sequencing resulted in no
significant increase in the error rates in the viral sequencing data
(ranging from 0.0012 to 0.0013 per bp; per-nucleotide error rate,
0.12%–0.13%).
To estimate the accuracy of detecting nucleotide alterations
using reads filtered by average base quality and mapping quality,
we introduced the plasmid with single point mutations within the
wild-type viral sequences with the ratio of 1:99 and 1:999 and
assessed the sensitivity and accuracy of quantification with the
high-fidelity PCR amplification followed by multiplex ultra-deep
sequencing. Duplicate control experiments revealed that muta-
tions present at an input ratio of 0.10% ranged between 0.09 and
0.19%, and the results could be reproducibly quantified (data not
shown). Based on these results, we picked up the low abundant
mutations that presented at frequency of more than 0.20% among
the total viral clones, a level that could rule out putative errors
caused by massively-parallel sequencing, in the current platform
used in this study.
Large heterogeneity of viral clones in HCV-infected
patients
HCV infection comprises a heterogeneous mixture of viral
clones with various mutations. To clarify the landscape of HCV
heterogeneity as a quasispecies, we determined the viral full-
genome sequences derived from 27 HCV-infected patients by
multiplex ultra-deep sequencing and compared the results with
those obtained by the direct population Sanger sequencing
method. All sequence reads by multiplex ultra-deep sequencing
have been deposit in DNA Data Bank of Japan Sequence Read
Archive (http://www.ddbj.nig.ac.jp/index-e.html) under acces-
sion number DRA000366.
HCV nucleotide sequence reads by ultra-deep sequencing were
aligned to the consensus viral sequences in the same serum
specimen that were determined by direct population Sanger
sequencing. A mean number of 1705-fold coverage on average
was achieved at each nucleotide site of the HCV sequences in each
specimen. The average frequencies of altered sequences detected
in each viral genomic region are summarized in Table 2.
Compared with the representative sequence of the population
average clone, the mutation frequency was 1.04% of the total viral
genomic sequences and 16.1% of the total nucleotide positions on
average. Most of the genomic changes observed in viral variants
were single base substitutions and unevenly distributed throughout
the region of the HCV genome.
Among the viral genomic regions, the nucleotide sequence
complexity expressed as the Shannon entropy was smallest in the
core region. In contrast, the viral sequence complexity in the E2
region was highest among the HCV genomic regions and
significantly greater than the average mutation frequency of the
remaining HCV genome (p=0.0026). Similarly, the ratio of the
number of mutated nucleotides to the total number of nucleotides
analyzed in the E2 region was significantly higher than that of the
remaining HCV genome (p=5.66610
26). These findings clearly
confirmed that the quasispecies complexity in E2, which contains
hypervariable region1 (HVR1) and HVR2, was prominently
larger than that of other viral genomic regions [19].
Table 1. Error frequency of ultra-deep sequencing for the
plasmid encoding full-genome HCV sequence.
PCR amplification
(2)* (+)*
Total read nucleotides 15,118,929 24,158,372
Mean coverage 1674.3 5562.6
Type of errors
mismatches 14,629 (94.8%) 26,243 (88.6%)
deletions 640 (4.2%) 2510 (8.5%)
insertions 147 (1.0%) 859 (2.9%)
Overall error rate (%) 0.102 0.123
*(2); Ultra-deep sequencing of HCV encoding plasmid
(+); Ultra-deep sequencing of PCR-amplified HCV encoding plasmid.
doi:10.1371/journal.pone.0024907.t001
Deep Sequencing of HCV Genetic Complexity
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administration of peg-IFNa2b plus RBV
Among 27 patients enrolled in this study, 8 showed a prompt
decrease in their serum HCV RNA levels and 8 showed no
significant changes 1 week after initiating treatment with peg-
IFNa2b plus RBV. To clarify the changes in the viral quasispecies
in response to antiviral therapy, we determined the early dynamic
changes in viral complexity before and after 1 week of peg-IFNa2b
plus RBV administration in these 8 immediate virologic
responders and 8 non-responders. All cases were infected with
genotype 1b viruses, and the clinical features, including serum
HCV RNA level at baseline, did not significantly differ between
immediate virologic responders and non-responders (Table 3). A
mean coverage of 1798-fold and 2416-fold were mapped to each
reference sequence in immediate virologic responders before and
after peg-IFNa2b plus RBV administration, respectively. Similar-
ly, a mean coverage of 1780-fold and 2461-fold were determined
in non-responders before and after peg-IFNa2b plus RBV
administration, respectively (Table 4 and Table S1).
We then estimated the genomic complexity by calculating the
Shannon entropy for each nucleotide position before and after the
administration of peg-IFNa2b plus RBV (Table 4). There was no
significant difference in the level of viral complexity between
immediate virologic responders and non-responders at a baseline
(mean Shannon entropy value 0.072 vs 0.075, p=0.39).
Immediate virologic responders, however, showed a significant
reduction in the nucleotide sequence complexity after the
administration of peg-IFNa2b plus RBV (mean Shannon entropy
value 0.072 vs 0.049, p=0.037), indicating that the viral
quasispecies nature after the peg-IFNa2b plus RBV treatment
Table 2. Mean genetic complexity of the genotype1b HCV in chronically infected 27 patients.
Viral genomic
Region
Mean number of aligned
nucleotides
Mean number of mutated
nucleotides Mean coverage Mutation frequency (%)
Mean
Shannon entropy
Core 779,839 5027 1361 0.61 0.045926
E1 739,220 7902 1360 0.99 0.064884
E2 1,382,907 19,724 1265 1.37 0.088584
p7 217,000 3237 1148 1.44 0.075829
NS2 673,579 8702 1073 1.19 0.075333
NS3 4,958,188 52,204 2619 0.93 0.060767
NS4A 427,677 5604 2640 1.32 0.072217
NS4B 1,209,000 17,485 1544 1.26 0.063190
NS5A 2,034,626 28,820 1518 1.28 0.067398
NS5B 2,720,417 27,449 1681 0.90 0.054805
Total 14,875,801 172,327 1705 1.04 0.062624
doi:10.1371/journal.pone.0024907.t002
Table 3. Characteristics of patients that showed immediate virologic response or non-response to PEG-IFNa2b plus ribavirin
combination therapy.
Immediate virologic responders Non-responders P-value
Age
{ 50.5 (45–68) 60 (55–69) 0.12
Sex (male/female) 5/3 5/3 1
Alanine aminotransaminase
{ (IU/l) 54 (15–198) 72 (30–143) 0.51
Total bilirubin
{ (mg/dl) 0.6 (0.4–1.8) 0.8 (0.4–1.4) 0.34
Platelet count
{ (610
4/mm
3) 18.9 (7.1–27.2) 16.7 (11.6–22.5) 0.68
HCV genotype 1b 1b
HCV viral load
{ (log IU/ml)
pre-treatment 6.6 (6.2–7.5) 6.9 (6.1–7.6) 0.43
after treatment 4.6 (4.0–5.2) 6.5 (6.1–6.8) 0.028
Final outcome 0.025
sustained viral response 6 0
Relapse 1 1
non-response 0 6
withdraw* 1 1
{ Values are median (range).
* The treatment was discontinued in one immediate virologic responder and one non-responder, due to the side effect of IFN and the development of liver cancer,
respectively.
doi:10.1371/journal.pone.0024907.t003
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this group. In contrast, no significant changes in the nucleotide
sequence complexity were observed in non-responder patients
before and after treatment with peg-IFNa2b plus RBV (mean
Shannon entropy value 0.075 vs 0.066, p=0.12). We then
examined whether specific nucleotide position might be associated
with the response to peg-IFNa2b plus RBV treatment in
immediate virologic responders, but complexity was not common-
ly shared at any specific nucleotide position that changed by more
than 50% after peg-IFNa2b plus RBV administration (data not
shown), indicating no association between the specific nucleotide
position and the response to peg-IFNa2b plus RBV treatment.
Elimination of minor viral clones by peg-IFNa2b plus RBV
therapy
Next, we compared the nucleotide complexity in each viral
genomic region of the immediate virologic responders with that of
non-responders before and after peg-IFNa2b plus RBV admin-
istration (Figure 1 and Table S2). In immediate virologic
responders, the peg-IFNa2b plus RBV therapy induced a
significant reduction in the nucleotide sequence complexity in all
viral genomic regions except NS4B. In contrast, non-responders
showed no significant change in the viral sequence complexity in
any viral genomic region. For example, there was no significant
difference in the mean complexity in the E2 region at baseline
between the immediate virologic responders and non-responders.
The administration of peg-IFNa2b plus RBV significantly reduced
the levels of nucleotide sequence complexity in the E2 region in all
the immediate virologic responders (mean Shannon entropy value
0.139 vs 0.085, respectively. p=0.012, Figure 1 and Table S2). In
contrast, no significant changes in the sequence complexity were
observed in the E2 (mean Shannon entropy value 0.083 vs 0.082,
respectively. p=0.89) regions in non-responder cases after
treatment with peg-IFNa2b plus RBV.
To examine whether certain viral clones in non-responders
showed sensitivity to IFN therapy, we investigated the sequence
complexity in HVR1 in the E2 region in detail before and after
peg-IFNa2b plus RBV therapy, because the HVR1 region
possessed one of the highest complexities among viral genomic
regions. In immediate virologic responders, the heterogeneity at
each nucleotide position was reduced in response to peg-IFNa2b
plus RBV administration (representative nucleotide changes are
shown in Figure 2A). In contrast, the ratio of mutated clones
among the total sequence reads determined at each nucleotide site
in HVR1 showed no significant change before and after the
administration of peg-IFNa2b plus RBV in the majority of non-
responders (Figure 2B), suggesting that very few viral clones
showed sensitivity to peg-IFNa2b plus RBV and were eliminated
after the administration of peg-IFNa2b plus RBV.
Detection of viral clones with drug-resistant mutations
Because none of the DAAs for HCV were approved by
Japanese health coverage at the time of this study, all patients
enrolled into this study were naı ¨ve to DAAs for HCV including
protease and polymerase inhibitors. Thus, we determined whether
the reported drug-resistant mutants exist spontaneously in nature
among treatment-naı ¨ve HCV-infected patients. For this purpose,
we examined the naturally prevalent mutations against HCV
protease and polymerase inhibitors in the 27 patients. The drug-
resistant mutations examined here included 9 mutations resistant
to NS3/4 protease inhibitors, including Telaprevir, Boceprevir,
TMC435350, ITMN191/R7227, MK-7009, and BI-201335, and
5 mutations resistant to NS5B polymerase inhibitors, including
Filibuvir, BI-207127, and R7128 [20].
The mean number of sequence reads at the nucleotide position
comprising mutations resistant to NS3/4A protease and NS5B
polymerase inhibitors among the 27 cases were obtained with
1179-fold and 1972-fold coverage, respectively. Based on the
detection rate of the low-level viral clones determined by the
control experiments, we picked up the drug-resistant mutants that
presented at a frequency of more than 0.2% among the total viral
clones. Based on these criteria, at least one resistant mutation was
detected in all subjects (Table 5). The mean prevalence of the 14
drug-resistant mutations ranged from 0.20% to 99.1% indicating
that the proportion of resistant mutations substantially differed in
each case. The T54S/A mutation resistant to Teraprevir and
Boceprevir in genotype 1b HCV [21] was the most commonly
detected (20 of 27 cases, 74.1%). The proportion of T54S/A
mutations among the total clones ranged from 0.21% to 86.9%
and thus substantially differed between cases. Other mutations
resistant to the NS3/4A protease-inhibitor were detected in 16 of
27 cases (59.3%) at V55A and Q80R/K, and 12 of 27 cases
(44.4%) at V36A/M. In contrast, no D168A/V/T/H mutation
resistant to ITMN191/R7227, MK-7009, TMC435350, and BI-
201335 was detectable. Regarding NS5B polymerase inhibitors,
the V499A mutation resistant to BI-207127, was most frequently
detected and 20 of 27 (74.1%) of subjects possessed the resistant-
mutant clones at levels 0.20% to 99.1% at baseline. Only one case
had the BI-207127-resistant P496A mutant clones and none had
the R7128-resistant S282T clones. Of the 27 subjects, 16 (59.3%)
harbored mutations resistant to at least four kinds of NS5B
polymerase inhibitors and/or NS3/4A protease-inhibitors. More-
Table 4. Genetic complexity at pre-treatment and 1 week after PEG-IFNa2b plus ribavirin combination therapy in immediate
virologic responders and non-responders.
Immediate virologic responders (N=8) Non-responders (N=8)
Pre-treatment 1 week after IFN therapy Pre-treatment 1 week after IFN therapy
Mean number of aligned reads 263,452 356,963 256615 354,398
Mean number of aligned nucleotides 16,632,186 22,438,125 16,248,820 22,379,922
Mean coverage 1798 2416 1780 2461
Mutation frequency (%) 0.96 0.63 1.13 1.11
Shannon entropy 0.072* 0.049* 0.075** 0.066**
Wilcoxon rank sum test.
* p=0.037.
** p=0.12.
doi:10.1371/journal.pone.0024907.t004
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Notably, 3 subjects harbored resistance to 8 of 9 antiviral drugs.
There was no significant association between the frequency of
drug-resistant mutations and the serum viral load (r=0.0678)
(Figure S1).
These findings indicate that drug-resistant HCV variants are
present in a considerable proportion among the chronically HCV-
infected, DAAs-naı ¨ve patients.
Discussion
Sequence heterogeneity, so-called quasispecies, is a common
feature of RNA viruses, including HCV [22]. Previous studies of
the viral genome with conventional Sanger sequencing methods
revealed that HCV infection comprises a cloud of closely related
sequence variants differing by as little as one nucleotide from a
population average sequence [23]. A number of studies have
aimed to clarify the significance of viral mutations in association
with clinical features, including viral persistency and chronicity,
degree of liver damage, response to treatment, and selection of
mutants resistant to anti-viral therapy. The quasispecies nature of
HCV, however, represents a major obstacle in determining the
significance of the viral clone with specific sequence characteris-
tics. Newly developed ultra-deep sequencing analysis allowed us to
clarify the whole picture of viral quasispecies present in chronically
HCV-infected patients. In the present study, ultra-deep sequenc-
ing determined a mean total of more than 10 million nucleotides
of the viral genome in each specimen, representing more than
1000 clones infecting each patient, thus demonstrating the
abundant genetic complexity of HCV.
It is well recognized that the HCV genome is heterogeneous at
the intra-individual level [9,10]. The current ultra-deep sequenc-
Figure 1. Changes in the genetic complexity of each HCV genomic region before and after the administration of peg-IFNa2b plus
RBV. Shannon entropy values at baseline (black bar) and 1 week after initiation of treatment with peg-IFNa2b plus RBV (white bar) in 8 immediate
virologic responders (A) and in 8 non-responders (B) are shown. * p,0.05, ** not significant. (Mean values 6 SD; n=8)
doi:10.1371/journal.pone.0024907.g001
Deep Sequencing of HCV Genetic Complexity
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heterogeneity, while the core region had the lowest sequence
heterogeneity among the viral genomic regions encoding different
functional viral proteins. More than 15% of nucleotides in the E2
region were mutated in all cases examined. These findings are
consistent with previous conventional Sanger sequencing-based
studies showing that HVR1 and HVR2 possess the highest
sequence diversity among the HCV genomic regions [19] and that
the highest values of mean Shannon entropy at the HCV 1a
population level are in the E2 region [24].
Various mutations in the HCV genome are associated with the
therapeutic response. For example, a number of mutations within
a so-called IFNa sensitivity determining region of NS5A are
closely associated with sensitivity to IFN-based anti-viral therapy
[25,26]. A recent study also showed that amino acid substitution in
the HCV core region could be a useful predictor of the virologic
response to peg-IFNa plus RBV combination therapy [27].
Although the findings of these studies suggested that certain
mutations in the representative HCV clone could predict
treatment outcome, it is unknown whether the specific viral clone
comprising those mutations directly displays sensitivity or
resistance to anti-viral therapy. In the present study, sequential
comparison of the HCV1b genome derived at baseline and at 1
week after the administration of peg-IFNa2b plus RBV demon-
Figure 2. Ratio of mutated nucleotides in the HVR1 region before and after administration of peg-IFNa2b plus RBV therapy.
Representative results of a immediate virologic responder (Patient#3) (A) and a non-responder (Patient#9) (B) are shown. The read numbers
(coverage) at each nucleotide position of the HVR1 (from 1
st nucleotide to 21
st nucleotide in E2 region) at pre-treatment (upper graphs) and 1 week
after initiating treatment with peg-IFNa2b plus RBV (lower graphs) are shown. Arrows indicate the nucleotide positions that showed the elimination
of minor mutant clones after administration of peg-IFNa2b plus RBV.
doi:10.1371/journal.pone.0024907.g002
Deep Sequencing of HCV Genetic Complexity
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viral clones comprising the previously defined mutational changes
that were associated with a response to anti-viral therapy.
Moreover, immediate virologic responders showed no common
baseline nucleotide alterations that are efficiently eliminated in
response to the administration of peg-IFNa2b plus RBV. Thus,
our data suggest that an HCV sequence variation itself at a specific
single nucleotide position does not directly reflect the virologic
features regarding the sensitivity to IFN therapy in each viral
clone, at least at the early stage of IFN administration. In contrast,
several studies have provided evidence of the pre-existence of viral
strains with an inherent resistance to IFN in patients who
subsequently experienced a viral breakthrough or relapse
[24,28]. Thus, there is room for further investigation to identify
IFN-resistant clones by comparing the viral clones at baseline with
those at the point of relapse using ultra-deep sequencing
technology.
Notably, a distinct pattern of dynamic changes of HCV
quasispecies was present between immediate responders and
non-responders. Immediate responders showed a significant
decrease of genetic complexity spanning all the viral genetic
regions, resulting in a more homogeneous viral population after 1
week of peg-IFNa2b plus RBV administration. In contrast, non-
responders showed no significant change in the genetic complexity
in any of the HCV genomic regions. Our findings are consistent
with the previous study showing that the early changes in HCV
quasispecies determined by E1/E2 sequences provided prognostic
information as early as the first 2 weeks after starting IFN therapy
[28]. Moreover, the findings that there is no difference in the level
of genetic complexity between early responders and non-
responders at baseline and that almost none of the pre-existed
HCV clones were eliminated in non-responder cases might suggest
that the absence of sensitivity to IFN treatment in non-responders
is due to host factors. Consistent with this hypothesis, recent
studies revealed that host genetic variations at the IL28B gene are
associated with a virologic response to peg-IFNa plus RBV
combination therapy [29-32]. Alternatively, it is possible that a
particular HCV protein of certain HCV mutants contributed to
the strong inhibition of IFN-mediated anti-viral response in the
liver of non-responders. Although dynamic changes in HVR1
sequences revealed that the minor viral clones were promptly
eliminated in immediate virologic responders, the originally-
inhabited major viral clones persisted 1 week after peg-IFNa2b
plus RBV administration. Thus, further analyses are required to
clarify how viral heterogeneity might be associated with the
response to anti-viral therapy.
DAAs are promising drugs that could be more effective than
peg-IFNa plus RBV therapy [33]. These DAAs include HCV
NS3/4A protease and NS5B RNA-dependent RNA polymerase
inhibitors, both of which have currently advanced to phase 1-3
trials. Increasing evidence, however, has clearly revealed that
monotherapy with DAAs poses a high risk for the selection of
resistant variants because of the high genetic heterogeneity of
HCV [20]. Several studies reported the low prevalence of DAAs
resistant mutants as the dominant clones in treatment-naı ¨ve cases
[21,34-36]. For example, Kuntzen et al showed that drug-resistant
mutations were detectable by conventional sequencing at
individual frequencies between 0.3% and 2.8% in a treatment-
naı ¨ve genotype 1 HCV-infected population [21]. In sharp
contrast, ultra-deep sequencing identified that DAAs-resistant
variants are common among treatment-naı ¨ve patients. Indeed,
ultra-deep sequencing showed that 26 of 27 (96%) treatment-naive
Japanese patients enrolled in this study possessed at least two
clones resistant to DAAs, while 70.2% of the mutants presented as
a very minor population (less than 1%) in each individual. It
remains unclear whether these minor drug-resistant mutations
have clinical significance, because the DAAs are not yet approved
here in Japan. Recent in vitro findings, however, showed that minor
but preexisting resistant mutants in HCV replicon cells were
selected and expanded after DAAs therapy [37]. Lu et al revealed
Table 5. Prevalence of anti-HCV drug resistant mutations among the treatment-naı ¨ve patients.
Residue and Position Drugs
Number of patients with
mutated clones (%)
Frequency of the mutated
clones (%)*
Resistant mutation to NS3/4A protease inhibitor
T54S/A Telaprevir Boceprevir 20/27 (74.1%) 0.49 (0.21–86.9)
V55A Boceprevir 16/27 (59.3%) 0.4 (0.23–1.53)
Q80R/K TMC435350 16/27 (59.3%) 0.36 (0.24–1.37)
V36A/M Telaprevir Boceprevir 12/27 (44.4%) 0.47 (0.20–0.88)
V170A/T Boceprevir 11/27 (40.7%) 0.52 (0.20–1.03)
A156T/V Telaprevir 7/27 (25.9%) 0.35 (0.20–0.80)
R155K/T/Q Telaprevir Boceprevir ITMN191/R7227 MK-7009
TMC435350 BI-201335
5/27 (18.5%) 0.42 (0.22–0.62)
A156S Telaprevir Boceprevir 3/27 (11.15) 0.35 (0.24–0.83)
D168A/V/T/H ITMN191/R7227 MK-7009 TMC435350 BI-201335 0/27 (0%)
Resistant mutation to NS5B polymerase inhibitor
V499A BI-207127 20/27 (74.1%) 0.59 (0.20–99.1)
M423T/I/V Filibuvir 12/27 (44.4%) 0.41 (0.21–1.48)
P495S/L/A/T BI-207127 9/27 (33.3%) 0.37 (0.21–0.87)
P496A/S BI-207127 1/27 (3.7%) 0.32
S282T R7128 0/27 (0%)
* Values are median (range).
doi:10.1371/journal.pone.0024907.t005
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0.18% in the treatment-naı ¨ve replicon population rapidly
increased upon treatment with DAAs in a dose-dependent
manner, reaching frequencies of 25% and 60% after 4 days of
treatment. These findings suggest that those preexisting minor
mutants might cause resistance against DAAs through the
selection of dominant mutations. Thus, the significance of low-
abundance variants in treatment-naı ¨ve patients requires further
exploration.
The present study raises two limitations of ultra-deep parallel
sequencing technology in the analyses of viral quasispecies. First,
because the massive parallel ultra-deep sequencing platform is
based on multitudinous short reads, it is difficult to separately
evaluate the association between nucleotide sites mapped to
different viral genome regions in a single viral clone. Indeed, it is
difficult to clarify the potential mutational linkage between
different viral genomic regions because of the short read length
of the shotgun sequencing approach. Second, it is difficult to
accurately analyze highly polymorphic regions such as the HVR
by ultra-deep sequencing, because mutation findings strongly
depend on mapping to the reference genome sequences. Thus,
utilization of both conventional and ultra-deep sequencing
technology might be necessary to fully clarify the significance
and clinical relevance of the prominent HCV genomic heteroge-
neity.
In summary, using ultra-deep sequencing technology, we clearly
demonstrated the extremely large genetic complexity in the
genotype1b HCV derived from chronically infected patients.
Although there was no significant difference in the level of viral
complexity between immediate virologic responders and non-
responders at baseline, immediate virologic responders, but not
non-responders, showed a rapid reduction in the viral sequence
variability at an early phase of peg-IFNa2b plus RBV adminis-
tration. We also showed that drug-resistant mutants were widely
present in treatment-naı ¨ve HCV-infected patients, indicating a
putative risk for the expansion of resistant clones to DAAs. Further
studies with a large number of patients are needed to fully
elucidate the significance of viral heterogeneity in the clinical
outcome of patients receiving anti-viral therapy.
Materials and Methods
Patients
The participants comprised 27 Japanese adult chronic hepatitis
patients with genotype 1b HCV infection and the mean baseline
level of serum HCV RNA determined by TaqMan RT-PCR
(Applied Biosystems, Foster City, CA) was 6.9 log IU/ml. All
patients received conventional peg-IFNa2b plus RBV combina-
tion therapy (Schering-Plough, Kenilworth, NJ) at Kyoto Univer-
sity and affiliated hospitals from February 2007 to December
2008. Indications for IFN-based combination therapy included
high serum values of alanine aminotransferase and positivity for
serum HCV RNA. Patients were treated with peg-IFNa2b
(1.5 mg/kg) once per week, combined with daily oral RBV for
48 weeks [38]. The RBV dose was 600 mg/day in patients
weighing less than 60 kg, 800 mg/day in those weighing at least
60 kg but less than 80 kg, and 1000 mg/day in those weighing
80 kg or more.
In this study, immediate virologic responders were defined as
patients whose serum HCV RNA levels declined by more than 2
log IU/mL after 1 week of treatment with peg-IFNa2b plus RBV,
while non-responders were defined as those whose serum HCV
RNA levels declined less than 2 log IU/mL after peg-IFNa2b plus
RBV administration. Of the original 27 patients, the serum before
and 1 week after initiating treatment with peg-IFNa2b plus RBV
of 16 cases was available for further analyses, and 8 of these cases
were defined as immediate virologic responders and 8 cases were
defined as non-responders. Among these non-responder cases, the
serum HCV RNA levels in 6 of 8 (75.0%) patients changed by less
than 1 log IU/mL after 1 week of treatment. The decline in HCV
RNA levels in the remaining 2 cases was slightly over 1 log IU/mL
(1.2 and 1.4 log IU/mL).
The ethics committee at Kyoto University approved the studies,
and written informed consent for participation in this study was
obtained from all patients.
Direct population Sanger sequencing
To define the representative reference sequences of full-length
HCV in each clinical specimen, all samples were first subjected to
direct population Sanger sequencing using Applied Biosystems
3500 Genetic Analyzer (Applied Biosystems, Foster City, CA) [39].
Serum samples were obtained before the start and at 1 week after
initiation of peg-IFNa2b and RBV combination therapy. Total
RNA was extracted from 140 mL of serum using a QIAamp Viral
RNA Mini kit (QIAGEN, Valencia, CA) and reverse-transcribed
in a volume of 20 mL with the One step RNA PCR Kit AMV
(Takara Bio, Ohtsu, Japan).
HCV genomes were amplified using Phusion High-Fidelity
DNA polymerase (FINZYMES, Espoo, Finland). Oligonucleotide
primers were designed to amplify the first-half (,5,000 bps) and
the latter-half (,4,500 bps) of the genotype 1b HCV genome
sequences (Table S3).
PCR products purified by the QIAquick Gel Extraction kit
(Qiagen) were assayed for direct sequencing [40]. Nucleotide
sequences of PCR products were determined using an ABI
Prism Big Dye Terminator Ready Reaction Kit (Applied
Biosystems). The serum of a healthy volunteer was used as a
negative control.
Massive-parallel ultra-deep sequencing
Paired-end sequencing with multiplexed tags was carried out
using the Illumina Genome Analyzer II. End-repair of DNA
fragments, addition of adenine to the 39 ends of DNA
fragments, adaptor ligation, and PCR amplification by
Illumina-paired end PCR primers were performed as described
previously [41].
Briefly, the viral genome sequences were amplified with high-
fidelity PCR and sheared by nebulization using 32 psi N2 for
8 min and the sheared fragments were purified and concentrated
using QIAquick PCR purification Kit (Qiagen). The overhangs
resulting from fragmentation were then converted into blunt ends
using T4 DNA polymerase and Klenow enzymes, followed by the
addition of terminal 39 adenine-residues. Next, one of the adaptors
containing six unique base pair (bp) tags, such as ‘‘ATCACG’’ and
‘‘CGATGT’’ (Multiplexing Sample Preparation Oligonucleotide
Kit, Illumina), was ligated to each fragment using DNA ligase.
Adaptor-ligated DNAs in the range of 200 to 350 bp were then
size-selected by agarose gel electrophoresis. These libraries were
amplified independently using a minimal PCR amplification step
of 18 cycles with Phusion High-Fidelity DNA polymerase and then
purified using a QIAquick PCR purification Kit for a downstream
assay. Cluster generation and sequencing was performed for 64
cycles on the Illumina Genome Analyzer II following the
manufacturer’s instructions. Obtained images were analyzed and
base-called using GA pipeline software version 1.4 with default
settings provided by Illumina.
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Using the high performance alignment software ‘‘NextGene’’
(SoftGenetics, State College, PA), the 64 base tags obtained from
the Genome Analyzer II reads were aligned to the reference HCV
RNA sequences of ,9200 bp that were determined by direct
population Sanger sequencing in each clinical specimen. Entire
reads were removed from the analysis when the median quality
value score was below 20 and when containing more than 3
uncalled nucleotides. The low quality bases were trimmed from
reads when more than 3 consecutive bases fell below a quality
value score of 16. Based on the above criteria, reads with 90% or
more bases matching a particular position of the reference
sequence were aligned. Each position of the viral genome was
assigned a coverage depth, representing the number of times the
nucleotide position was sequenced.
Statistical analysis
Results are expressed as mean or median values and range
(minimum and maximum). Pretreatment values were compared
using the Mann–Whitney U-test. Categorical variables were
analyzed by Fisher’s exact test. P values of less than 0.05 were
considered statistically significant. The viral quasispecies nature
was evaluated by analyzing the genetic complexity based on the
number of different sequences present in the population. Genetic
complexity was determined by Shannon entropy values calculated
as follows:
Sn~{
Pn
i~1 fi lnfi ðÞ
N
where n is the number of different species identified, fi is the
observed frequency of the particular variant in the quasispecies,
and N is the total number of clones analyzed [23,42]. Statistical
comparisons of complexity between two groups were made using
the Wilcoxon rank sum test or the Mann–Whitney U-test.
Supporting Information
Figure S1 Relationship between serum HCV RNA levels
and the number of resistant mutant. No correlation was
observed between serum HCV RNA levels (log IU/ml) and the
number of resistant mutations against direct-acting antivirals in 27
cases in this study.
(TIF)
Table S1 Aligned reads, nucleotides, and mean coverage of each
reference sequence in all patients.
(DOC)
Table S2 Mean genetic complexity in each viral genomic region
of the 8 immediate virologic responders and 8 non-responders at
pre-treatment and 1 week after IFN therapy.
(DOC)
Table S3 The oligonucleotide primers for PCR amplifying the
whole HCV sequences.
(DOC)
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